Journal
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Volume 204, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.jpba.2021.114285
Keywords
Spectroscopy; Circulating nucleic acids; Circulating RNA; Point of care test; Translational research
Categories
Funding
- Indian Council of Medical Research (ICMR), Department of Health Research (DHR), Ministry of Health & Family Welfare (MoHFW), Government of India, New Delhi
Ask authors/readers for more resources
Lateral flow assay (LFA) is a flexible, simple, and low-cost platform for rapid detection of disease specific biomarkers. This article reviews the innovative concept of LFA-based detection of circulating long non-coding RNAs (lncRNAs) and discusses their potential application in cancer detection.
Lateral flow assay (LFA) is a flexible, simple, low-costpoint-of-care platform for rapid detection of disease specific biomarkers. Importantly, the ability of the assay to capture the circulating bio-molecules has gained significant attention, as it offers a potential minimal invasive system for early disease diagnosis and prognosis. In the present article, we review an innovative concept of LFA-based detection of circulating long non-coding RNAs (lncRNAs), one of the key regulators of fundamental biological processes. In addition, their disease-specific expression pattern and presence in biological fluids at differential levels make them excellent biomarker candidates for cancer detection. Our article also provides an update on the requirements for developing and improving such systems and discusses the key aspects of material selection, operational concepts, principles and conceptual design. We assume that the reviewed points will be helpful to improve the diagnostic applicability of LFA based lncRNA detection in cancer diagnosis. (c) 2021 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available